BDBM509563 US11364246, Example 2.7::US20200361871A1, Example 2.7

SMILES CC(C(=O)Nc1cccc(c1)C(=O)NC(C)(C)C)c1ccccc1O

InChI Key InChIKey=UGYDCHCEPFCLHV-UHFFFAOYSA-N

Data  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 509563   

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509563(US20200361871A1, Example 2.7 | US11364246, Example...)
Affinity DataEC50:  8.19E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
Go to US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509563(US20200361871A1, Example 2.7 | US11364246, Example...)
Affinity DataEC50:  8.19E+3nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
Go to US Patent